Decreased Tenofovir Diphosphate Concentrations in a Transgender Female Cohort: Implications for Human Immunodeficiency Virus Preexposure Prophylaxis.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30963179.
- Also identified by DOI 10.1093/cid/ciz290 and PMC identifier 7188232.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Feminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP's active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = -0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy. Clinical Trials Registration . NCT02983110.
Medical subject headings
- Adenine
- Anti-HIV Agents
- HIV
- HIV Infections
- Organophosphates
- Pre-Exposure Prophylaxis
- Transgender Persons